T

hey call it the “Proteus effect.”

Researchers tracking clinical trials have long been aware that the first studies to be published sometimes show benefits that aren’t borne out in later trials. Like Proteus, the Greek god of the sea who could change his shape, evidence can shift over time to show more modest improvements.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • This isn’t shocking. Lots of early phase studies, half show higher than true effect, half show lower (and more than half if they study multiple doses due to multiplicities). Then only the high-effect studies move forward. Then upon subsequent, larger, studies we get regression to the mean as expected. Precisely why so many late-stage studies fail — trial designers fail to account for regression to the mean that’s bound to occur in later stages.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy